Madeline Lancaster, a researcher at the Institute of Molecular Biotechnology at the Austrian Academy of Science in Vienna and her colleagues, created "cerebral organoids" that have components resembling a brain of a 9- or 10-week-old embryo. These can help researchers explore important questions about brain development and disorders that occur during these first stages of life. Click here for more on this story.
While this is great, the stem cell as a sustainable therapy for the manufacturer, the patient and public health in general has a funding gap to go. The few that we thought made it to the finish-line were practically false starts, and the next to commercialize are scratching their heads – large cap investors won't budge. Meanwhile, who knows; the treatment for cancers, HIV, Parkinson's, Alzheimer's, MS â¦ could really be a stem cell.
Join stem cell companies on September 30 – October 1 as we try and figure out how we can go one step further. Click here for more details